NEW YORK, March 21, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Obagi Medical Products, Inc. ("OMPI" or the "Company") (NASDAQ: OMPI) concerning the proposed acquisition of the Company to Valeant Pharmaceuticals International, Inc. ("Valeant") in a transaction valued at approximately $360 million.
On March 20, 2013, OMPI announced that it had entered into a definitive agreement pursuant to which the Company will be acquired by Valeant. Under the terms of the agreement, OMPI stockholders will receive $19.75 in cash for each share held.
Our investigation concerns whether the OMPI board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.
If you own OMPI shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin Sachs-Michaels, Esq. Robert I. Harwood, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email: firstname.lastname@example.org Website: http://www.hfesq.com
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP